View from the C-Suite: Aras Azadian, Chief Executive Officer, Avicanna Inc., tells his company’s story.

View from the C-Suite: Aras Azadian, Chief Executive Officer, Avicanna Inc., tells his company’s story. Filmed on July 18, 2019

The View from the C-Suite video interview series highlights the unique perspectives of listed companies on Toronto Stock Exchange and TSX Venture Exchange.  Videos provide insight into how company executives think in the current business environment.  To see the latest View from the C-Suite videos visit www.tmxmoney.com/en/news/csuite.html)

About Avicanna Inc. (TSX: AVCN)

Avicanna is an Ontario corporation focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.

Avicanna’s two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa MartaColombia are the base for Avicanna’s cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).

Avicanna’s research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna’s scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.

Avicanna’s research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.

About TMX Group (TSX: X)

TMX Group’s key subsidiaries operate cash and derivative markets and clearinghouses for multiple asset classes including equities and fixed income. Toronto Stock ExchangeTSX Venture ExchangeTSX Alpha ExchangeThe Canadian Depository for SecuritiesMontréal ExchangeCanadian Derivatives Clearing CorporationTrayport and other TMX Group companies provide listing markets, trading markets, clearing facilities, depository services, technology solutions, data products and other services to the global financial community. TMX Group is headquartered in Torontoand operates offices across North America (Montréal, CalgaryVancouver and New York), as well as in key international markets including LondonBeijing and Singapore. For more information about TMX Group, visit our website at www.tmx.com. Follow TMX Group on Twitter: @TMXGroup.

SOURCE TMX Group Limited

Click Here

Avicanna Announces Commencement of Clinical Trials for Derma-Cosmetics

Avicanna Announces Commencement of Clinical Trials for Derma-Cosmetics

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/

TORONTOJuly 24, 2019 /CNW/ – Avicanna Inc. (“Avicanna” or the “Company“) a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce the commencement of phase I clinical trials on three of its derma-cosmetic products.

Centro de Atención e Investigación Médica CAIMED S.A.S. (“CAIMED“) has commenced clinical studies on Avicanna’s Pura Earth™ derma-cosmetics products in order to demonstrate their effectiveness with specific cosmetic endpoints, such as reduction of fine lines associated with aging, efficacy as a moisturizer for eczema prone skin, and reduction of sebum and redness attributed to acne. In connection with such clinical studies, CAIMED is currently in the process of recruitment for the Company’s intensive conditioner trial for eczema prone skin and expects recruitment for the clear skin and regenerative serum trials to begin in August, with a total of 54 patients expected to be recruited per trial. Once applications have been administered to patients, the trials for clear skin and intensive conditioner are expected to last four weeks with the trial for the regenerative serum expected to last eight weeks. The studies are being completed in Colombia and results are expected to be available prior to commercial launch during the fourth quarter of 2019. Additionally, the Company is unaware of any other trials on https://clinicaltrials.gov involving cannabinoids in Colombiaor on derma-cosmetics containing cannabinoids in the world.

“At CAIMED we are very excited and proud of leading the medical cannabis clinical research with Avicanna´s dermatology and cosmetic products. The studies have been designed and are being developed with the highest standards in order to build strong evidence in this new challenging heath care opportunity” said Humberto Reynales, Executive Director of CAIMED.

Dr. Amza Ali, Chief Medical Officer of Avicanna added “These trials in topical derma-cosmetics represent Avicanna’s strong commitment to evidence-based best practice generated through our overarching model of rigorous scientific R&D, with the ultimate objective of providing safe and truly efficacious cannabinoid-based products.”

About Pura Earth™

Pura Earth™ is Avicanna’s derma-cosmetic line which utilizes a combination of purified cannabidiol (CBD) and other synergistic botanical ingredients designed to naturally regulate and nourish the skin. The Pura Earth™ products are formulated with purified CBD extracted from Cannabis plants cultivated under organic and sustainable conditions by Avicanna’s subsidiary, Santa Marta Golden Hemp S.A.S., which is located in Santa MartaColombia in the foothills of the Sierra Nevada Mountains. The Pura Earth™ product line was designed by Avicanna and optimized in partnership with the University of Toronto using Avicanna’s proprietary formulations. The Pura Earth™ product line will be manufactured by Altea Farmaceutica S.A. (“Altea“) under Good Manufacturing Practices standards. Avicanna has completed the technical transfer of all Pura Earth™ products to be manufactured by Altea and Altea has commenced production for both testing and commercial scale production purposes. Avicanna has entered into an agreement with Percos S.A. (“Percos“) pursuant to which it has appointed Percos as the exclusive distributor of Pura Earth™ derma-cosmetics products in Colombia, subject to certain minimum sales volumes and the Company anticipates that its Pura Earth™ derma-cosmetics products will be on the market before the end of 2019. Once the clinical studies have been completed Avicanna intends to investigate additional markets where CBD cosmetics are permitted both through retail and Avicanna’s own e-commerce platform.

About CAIMED

CAIMED is a provider of health solutions based on data science, information and knowledge management. CAIMED also provides contract research and site management organization services to the life sciences industry in Latin America. CAIMED was founded in 2007 in Colombia and has included more than 20,000 subjects in clinical studies in multiple therapeutic areas. Powered by MetricsMed™, CAIMED offers unique software technology for efficient management of clinical research operations for sites and ethics review committees.

About Avicanna

Avicanna is an Ontario corporation focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.

Avicanna’s two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa MartaColombia are the base for Avicanna’s cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).

Avicanna’s research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna’s scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.

Avicanna’s research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.

Cautionary Note Regarding Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only Avicanna’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of Avicanna’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein may include, but is not limited to, the expected timing required to complete clinical trials, the expected timing to commence recruitment, the expected timing to complete recruitment, the expected number of patients, the intention of the Company to explore additional markets and the commencement of production of the derma-cosmetic products.

By identifying such information and statements in this manner, Avicanna is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Avicanna to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, Avicanna has made certain assumptions.

Among others, the key factors that could cause actual results to differ materially from those projected in the forward-looking information and statements are the following: decreases in the prevailing prices for cannabis and cannabis products in the markets in which the Company operates; adverse changes in applicable laws; adverse changes in the application or enforcement of current laws, including those related to taxation; increasing costs of compliance with extensive government regulation; changes in general economic, business and political conditions, including changes in the financial markets and in particular in the ability of the Company to raise debt and equity capital in the amounts and at the costs that it expects; risks related to licensing, including the ability to obtain the requisite licenses or renew existing licenses for the Company’s proposed operations; dependence upon third party service providers, skilled labor and other key inputs; risks inherent in the agricultural and retail business; intellectual property risks; risks related to litigation; dependence upon senior management; and the other risks disclosed in the Company’s long form final prospectus dated July 8, 2019. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although Avicanna believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. Key assumptions used herein are that there will not be any unforeseen delays in the completion of the clinical trials being conducted by CAIMED, CAIMED will be able to find suitable participants in a timely manner and there will not be any unforeseen delays in the manufacture, for commercial production, of the Company’s derma-cosmetic product line. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and Avicanna does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to Avicanna or persons acting on its behalf is expressly qualified in its entirety by this notice.

SOURCE Avicanna Inc.

For further information: about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email info@avicanna.com.

Stay Connected

SOURCE Avicanna Inc.

Click Here

Avicanna Commences Trading on the TSX Under the Symbol “AVCN”

Avicanna Commences Trading on the TSX Under the Symbol “AVCN”

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/

TORONTOJuly 18, 2019 /CNW/ – Avicanna Inc. (“Avicanna“) a company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that its common shares commenced trading on the Toronto Stock Exchange (the “TSX“) under the symbol “AVCN” at market open today, July 18, 2019.

In connection with its first day of trading, Avicanna participated in market open ceremonies at the TSX. An archive of the ceremony will be made available at http://www.tsx.com/news/market-opens.

About Avicanna

Avicanna is an Ontario corporation focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.

Avicanna’s two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa MartaColombia are the base for Avicanna’s cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).

Avicanna’s research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna’s scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.

Avicanna’s research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.

Stay Connected

SOURCE Avicanna Inc.

Click Here

Avicanna Announces TSX Listing Date

Avicanna Announces TSX Listing Date

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES . ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/

TORONTO , July 16, 2019 /CNW/ – Avicanna Inc. (“Avicanna” or the “Company“) a company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, is pleased to announce that its common shares (“Common Shares“) are expected to commence trading on the Toronto Stock Exchange (the “TSX“) on Thursday, July 18, 2019 under the symbol “AVCN”. The listing represents the first direct listing on the TSX by a company with Colombian-based cannabis cultivation assets. In connection with its first day of trading, Avicanna will be participating in market open ceremonies at the TSX, which will be broadcast live on the Business News Network morning show and live streamed on YouTube.

In connection with listing on the TSX, shareholders holding an aggregate of 10,523,077 Common Shares have entered into lock-up agreements pursuant to which they have agreed not to sell, transfer or pledge any securities of the Company for a period of 39 months following the listing date where 10% of such securities will be released on the date that is three months following the listing date with the remaining securities released in six equal tranches of 15% every six months following the first release. In addition, shareholders holding an aggregate of 1,495,022 Common Shares have entered into lock-up agreements pursuant to which each such shareholder has agreed not to sell, transfer or pledge any securities of the Company held by such shareholder, for a period of 4 months following the listing date where 20% of such securities will be released immediately prior to the listing date with the remaining securities released in four equal tranches of 20% every month thereafter.

About Avicanna

Avicanna is an Ontario corporation focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products through its two main business segments: (i) cultivation and (ii) research and development. The Company’s business is focused on the development, manufacturing, and commercialization of key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics and extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates).

Research and Development Activities

Avicanna’s research and development is headquartered in the Johnson & Johnson Innovation Centre, JLABS @ Toronto . The Company is focused on commencing and completing clinical trials for its pharmaceutical products, completing testing to support its phyto-therapeutic products under the Pura Elements™ brand, commencing the manufacture and distribution of its derma-cosmetic products under the Pura Earth™ brand, and commencing clinical trials on three of its derma-cosmetic products to demonstrate their effectiveness with specific cosmetic endpoints, such as reduction of fine lines or increased skin moisture levels.

In connection with its research and development activities, Avicanna has a team of more than 20 scientists and clinicians working out of four laboratories including: (i) the University of Toronto Faculty of Pharmacy; (ii) JLABS @ Toronto which is located in the MaRS Discovery District; (iii) the facilities of the Company’s subsidiaries in Santa Marta , Colombia ; and (iv) the facilities of Avicanna’s manufacturing partner, Altea Farmaceutica S.A. (“Altea“). Through its various operations, Avicanna’s team of scientists and clinicians are enhancing product optimization through the completion of animal pharmacokinetics and toxicology studies and pre-clinical studies, including both in vitro and in vivo studies to demonstrate the safety and efficacy of Avicanna’s product offering.

Click Here

Avicanna Announces Receipt for Final Prospectus and Conditional Approval for Listing on the TSX

Avicanna Announces Receipt for Final Prospectus and Conditional Approval for Listing on the TSX

TORONTOJuly 10, 2019 /CNW/ – Avicanna Inc. (“Avicanna” or the “Company“) a company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that it has obtained a receipt for its final long form prospectus (the “Prospectus“) filed in connection with its completed special warrant offering for gross proceeds of approximately $22.1 million (the “Offering“). The Offering was led by Sprott Capital Partners LP and included Paradigm Capital Inc.

The Prospectus qualified the distribution of 2,228,328 common shares of the Company (the “Common Shares“) and 1,114,164 common share purchase warrants (the “Warrants“) issuable for no additional consideration upon the exercise or deemed exercise of special warrants of the Company (the “Special Warrants“) issued under the Offering.  Each Warrant entitles the holder thereof to acquire one Common Share until April 15, 2021 at a price of $10 per Common Share, subject to acceleration in certain circumstances.

As a result of obtaining the receipt for the Prospectus, all unexercised Special Warrants will be automatically exercised on July 15, 2019 without any further action on the part of the holders.

A copy of the Prospectus is available on SEDAR at www.sedar.com.

The Company has received conditional approval from the Toronto Stock Exchange (the “TSX”), one of Canada’s senior stock exchanges, for the listing of the Common Shares on the TSX as an Industrial (Research & Development) issuer, subject to the completion of customary requirements of the TSX, including the receipt of all required documentation. Following receipt of final approval from the TSX, the Common Shares are expected to commence trading on the TSX under the symbol “AVCN”.

No securities regulatory authority has either approved or disapproved the contents of this news release. The Common Shares and Warrants have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“) or any state securities laws. Accordingly, the Common Shares and Warrants may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to exemptions from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any securities of the Company in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

About Avicanna

Avicanna is an Ontario corporation focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products through its two main business segments, cultivation and research and development.

Avicanna’s two majority-owned subsidiaries, Sativa Nativa S.A.S. and Santa Marta Golden Hemp S.A.S., both located in Santa MartaColombia are the base for Avicanna’s cultivation activities. These two companies are licensed to cultivate and process cannabis for the production of cannabis extracts and purified cannabinoids including cannabidiol (CBD) and tetrahydrocannabinol (THC).

Avicanna’s research and development business is primarily conducted out of Canada at its headquarters in the Johnson & Johnson Innovation Centre, JLABS @ Toronto. Avicanna’s scientific team develops products, and Avicanna has also engaged the services of researchers at the Leslie Dan Faculty of Pharmacy at the University of Toronto for the purpose of optimizing and improving upon its products.

Avicanna’s research and development and cultivation activities are focused on the development of its key products, including plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics and Extracts (defined as plant-derived cannabinoid extracts and purified cannabinoids, including distillates and isolates), with a goal of eventually having these products manufactured and distributed through various markets.

Cautionary Note Regarding Forward-Looking Information and Statements

Certain information in this press release contains forward-looking statements. Such statements include but are not limited to the Company’s intention to list the Common Shares on the TSX, the expected trading symbol for the Company, the conversion of the Special Warrants and Avicanna’s business plan regarding the development, manufacturing and commercialization of plant-derived cannabinoid-based products. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict, including the risk that the Company may not be able to secure a listing on the TSX and certain other risk factors set out under the heading “Risk Factors” in the Prospectus. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements, unless and until required by securities laws applicable to the Company.

SOURCE Avicanna Inc.

For further information: Stay Connected – For more information about Avicanna, visit www.avicanna.com, call 1-647-243-5283, or contact Setu Purohit, President by email info@avicanna.com.

Click Here

Alianza de cannabis medicinal entre las empresas Avicanna y Altea

Alianza de cannabis medicinal entre las empresas Avicanna y Altea

Se realizó el lanzamiento de la alianza entre Avicanna, empresa canadiense de cannabis medicinal, y Altea, laboratorio colombiano certificado internacionalmente, que se llevó a cabo en las instalaciones de Altea. Las compañías decidieron unirse para exportar medicamentos a base de cannabis medicinal. En la foto: Justin Grant, vicepresidente de asuntos científicos de Avicanna; Aras Azadian, CEO de Avicanna; Janeth Mora, vicepresidente de desarrollo comercial de Avicanna; Néstor Negrete, gerente de operaciones de Altea; Amza Ali, director médico de Avicanna; y Carlos Maldonado, director médico en Colombia de Avicanna.

Click Here

Avicanna Inc is a well funded bio pharmaceutical company that is ready to go public

Avicanna Inc is a well funded bio pharmaceutical company that is ready to go public

Avicanna CEO Aras Azadian joined Steve Darling from Proactive Investors in our Toronto Studio to discuss their BioPharma company that is using cannabinoids in its products. With its vertical integration, Avicanna has developed a derma-cosmetic line, a phytotherapeutic line, and is in various stages of clinical testing for pharmaceutical development

Azadian telling Proactive about their recent fundraise and how they are taking a big step forward by going public.

Click Here

We Visited Some Cannabis Grows In Colombia To Figure Out If The Hype Is Real

We Visited Some Cannabis Grows In Colombia To Figure Out If The Hype Is Real

“To determine if Colombia’s cannabis scene is actually all that, we had to see it to believe it.”

If you’ve been keeping up with the state of the international cannabis industry, then you’ve probably heard of Colombia being poised as the next major hub for cannabis exports.

With the perfect climate and geography for cultivation, low production costs, a vast network of experienced professionals in the field (illegal experience is still experience!), and the green-light from the INCB (International Narcotics Control Board) to grow and export over 25 percent of the world’s total production quota (40.5 tonnes), Colombia has had investors drooling over the chance to break into the world’s next star in the realm of legal cannabis.

“To date in the legal cannabis industry, it’s largely been all about indoor, high-end flower as a key product category. Going forward, the growth of concentrates, edibles, and pharmaceuticals means that this will less and less be the case,” said Tom Adams, managing director and principal analyst at BDS Analytics. “Colombia’s advantages as a low-cost, outdoor growth venue will place the country’s cultivators in good stead in worldwide markets.”

Here’s BDS’ Colombia forecast, with international and global spending toplines:

  • International Spending – Accounts for legal spending in countries outside of North America (US and Canada).
  • Global Spending – Accounts for spending in all legal markets.
  • *All spending estimates are in Millions of US dollars

However, skeptics may look hard past all the buzz to wonder if Colombia’s purported role as a major supplier for Canada’s legal market is no more than hype, created by speculation around the rising South American pot star’s favorable regulations and media coverage of Canadian firms investing in its soil.

So to determine if Colombia’s cannabis scene is actually all that, we had to see it to believe it. With our bags packed with as many pairs of shorts our closets had to offer, a collection of sunglasses and the remains of last summer’s sunscreen lotions, we headed down there for a first-hand take on the situation.

We landed at an airport by the sea in the Caribbean city of Santa Marta, where we would check out a couple farms owned and operated by Avicanna — a Canadian cannabinoid research company that recently partnered with one of the largest agro companies in the world. To date, it’s also the only cannabis-focused company to be accepted into Johnson & Johnson’s incubator, JLABS @ Toronto – as reported by High Times in 2017.

All details aside, the farm extinguished any doubt left in our minds about cannabis in Colombia: The land of Shakira and Carlos Vives is exploding with more than just pop music!

A Little Context
Just last month, the Colombian company Ecomedics S.A.S. (doing business as Clever Leaves) became the first to legally ship cannabis to Canada, in what became the first export to ever receive authorization from both Health Canada and the Colombian National Narcotics Fund.

Other big, publicly-traded companies like Khiron Life Sciences, Pharmacielo, Aphria, the Wayland Group, Chemesis International, the Cronos Group, Canopy Growth, and Aurora Cannabis have also made multi-million dollars investments in the country.

Colombia actually began tracing a path towards legalization almost 30 years ago, when Law 30 passed, which legalized medical production. However, it wasn’t until 2015 that a set of regulations was established, and the production of cannabis was officially legalized.

Today, psychoactive and non-psychoactive forms of cannabis are legal, provided they’re bred for medical and scientific purposes. Recreational adult use remains illegal but possession of up to 20 grams and cultivation of up to 20 plants is decriminalized by the Supreme Court.

Regulations governing cannabis exports are still evolving: New Frontier Data’s 2019 report on the Latin American Cannabis Market states that only oil-based products are allowed to be exported. Even the Clever Leaves landmark shipment is still more promise than fact, since that first exported batch is meant only for lab testing, rather than for sale.

From 0 To 100 In A Second

We first visited Avicanna’s cannabis farms in May of 2018, as part of a trip that revolved around a symposium on medical cannabis in Santa Marta.

The Avicanna team mentioned they were building out one of the first legal marijuana grows in Colombia, and offered to give us a tour. They warned us there was not much there yet, except for a few buildings and some workers. However, the dream-like scenery of a soon-to-be mountainous cultivation site, just miles away from white sandy beaches and the even whiter snowy peaks, was definitely a sight to behold.

With no idea of the magic awaiting us at Avicanna’s grounds, we visited the same day, as it turned out, that the company’s first small plantlets arrived from their nursing and propagation facility. As the team prepared to plant each tiny clone carefully into its pot, we realized this would become an all-nighter: The plants had to be in the ground before the sun rose again so that their cycles would remain unchanged.

We observed legendary master grower Sergio Puerta (who has more than 30 years’ experience growing weed) smile to see his babies planted legally, for the first time ever. Puerta has lost friends, sleep, and entire crops to senseless prohibition policies — hence, the prospect of growing cannabis out in the open was a dream come true. Even his parents and wife were there to witness the historic moment.

After our visit to Avicanna, we spent the rest of the week at the symposium, speaking with cannabis scientists, executives, and growers about Colombia’s destiny to become a world-class cannabis producer. Yet, however interesting these conversations were, they left us somewhat disappointed — the concept of weed fields stretching for miles on end seemed to be more talk than reality.

At the time, Colombia’s “cannabis” fields, were empty, save for a few bulldozers roaming about. We then learned, however, that all licensed cannabis growers were just starting out, since back then, the state had only recently issued permits.

Return To The Hempire

As months went by, we wondered about what might become of Colombia’s potential to become one of the largest cannabis producers in the world. We figured that potential was bound to be realized sooner rather than later, especially considering that it takes five cents to produce a gram of cannabis in Colombia, versus $1.50 in Canada.

But while there was a lot to say about Colombia’s potential, we had yet to witness material proof of it actually becoming this promised land of pot. For all we knew, this could easily be a flunk.

Then, in early January — more than six months after our last visit to Colombia — we we got a call from Aras Azadian, Avicanna’s CEO working out of the company’s Canadian headquarters, and Lucas Nosiglia, the firm’s president for Latin America.

“We’re about to start the harvest,” they told us, and we jumped at the prospect of getting to see Colombia’s first-ever commercial cannabis harvest. Two weeks later, we boarded a plane in Miami (with unjustified fears of airport delays caused by the U.S. government shutdown) and within a few hours, we were back. Having stashed our sweaters in our bags, we were now soaking up the Caribbean sun.

A driver wearing a company V-neck was waiting for us outside the sea-side airport. We joined him on the back of a huge pickup truck and drove away. It felt like we were characters in an old drug cartel movie, about to meet the powerful drug lord to strike a deal. But no, we shook our heads, that was an old-world paradigm.

Colombia was now going legal, and everything we were doing there was strictly within the law. We settled into a sense of comfort, lending itself to excitement, as we awaited to see what these guys had accomplished in only six months.

Out of Our Dreams

Our tour began at a lab and an indoor grow. Everything looked alright, unexpectedly high-tech (especially considering we were in the middle of the mountains in the Caribbean), but altogether in line with what we’d seen before on our many tours through American cultivation facilities.

The peopled guiding us smiled. They knew what we most looked forward to seeing, but of course, Colombians know to keep the best course for dessert.

As we walked up the hill, each step felt like a heartbeat. We knew we were about to see the same babies all grown, but we didn’t expect the scene to look so much like our fantasy: a vast field of open-air crops, rooted in the soil, and protected only by a thin canvas ceiling.

The pictures speak the rest.

They first took us through the characterization and research area (or ‘ship’, as they called them), where stood roughly 60 different cannabis varieties, all ripe and ready to harvest. Next up, were the commercial ships. In there, all plants looked exactly the same — and with good reason, as the company is only cultivating two stains of low-THC, CBD-dominant strains for commercial purposes — both for the Colombia’s legal medical market and for exports.

Click Here

Inversión de Avicanna llegará a US$10 millones en 12 meses

La firma canadiense tiene 20 hectáreas para cultivos de cannabis medicinal.

Con la instalación de 20 hectáreas de cultivo ubicadas 10 kilómetros a las afueras de Santa Marta en el Magdalena, Colombia se convirtió desde hace poco más de un año en la casa de Avicanna, una compañía de origen canadiense que cultiva, desarrolla y comercializa productos derivados del cannabis para fines médicos.

Sobre los proyectos de la firma, que opera en el Johnson & Johnson Innovation Center del MaRS de Toronto, las bondades del marco regulatorio local y la inversión de US$10 millones que se ejecutará en los próximos 12 meses para competir en Colombia y exportar a otros mercados, habló Aras Azadian, CEO de Avicanna.

¿Cuál es el enfoque operativo de Avicanna?
Avicanna nació hace más de tres años en Canadá y es la única compañía que tiene un enfoque exclusivamente médico y científico, más allá de la aprobación recreacional que regirá en nuestro país en octubre. En este tiempo nos hemos ocupado de hacer una investigación dedicada del cannabis medicinal con instituciones académicas y de la salud para aportar al desarrollo de esta área.
Además, estamos en el MaRS, un ecosistema tanto académico como médico en el que también están University of Toronto, University Health Network y Johnson & Johnson.

¿Qué encontraron atractivo en Colombia para concentrar sus inversiones aquí?
Fue una decisión que tomamos hace más de un año y medio a raíz de la legislación que se aprobó en el país y que ofrece la posibilidad de cultivar el cannabis medicinal en condiciones más competitivas. Colombia tiene oportunidades, por ejemplo en clima, que se traducen en un producto de óptima calidad y a menor precio. Eso va en sintonía con nuestra filosofía que es proveer productos a los pacientes que realmente lo requieren.

Pero, además, hace un año y medio también cerramos una alianza con el grupo Daabon, que es un actor de talla mundial, reconocido por sus prácticas sostenibles y orgánicas, que nos permitirán tener una producción realmente diferente. Creemos que esa es nuestra ventaja competitiva.

¿Cuál es el proyecto que tienen en el país?
En este momento la compañía está trabajando en un plan estratégico importante. Hoy, mercadeamos productos en Estados Unidos (California) y en Canadá. Pero, en paralelo, estamos trabajando para exportar a Europa y para cultivar, transformar y comercializar en Colombia. Por el momento, tenemos una oficina en Bogotá y un cultivo en Santa Marta.

¿Qué extensión tiene ese terreno?
Tenemos dos espacios a unos 10 kilómetros a las afueras de Santa Marta, cerca de la Sierra Nevada. Uno tiene 17 hectáreas y el otro es de tres hectáreas con posibilidad de ser ampliados. No obstante, por el tamaño de la demanda, no hemos visto la necesidad de hacerlo en el corto plazo.

¿En cuánto tiempo empezarían a cultivar?
Avicanna ya cuenta con todas las licencias. Sin embargo, hay un tema complejo que tiene que ver con la caracterización de las semillas y con las iniciativas del Gobierno Nacional que buscan escoger las especies idóneas para fines médicos. Ya estamos en ese proceso y, por ende, ya estamos cultivando en ambos terrenos diferentes variedades.

¿A cuánto ascendió la inversión de la compañía para entrar a competir en Colombia?
Hasta ahora, hemos invertido unos US$3 millones en la operación de Colombia. Pero a eso tenemos que sumarle lo que tiene que ver con la alianza estratégica que hicimos y que nos implicará invertir más de US$10 millones en los próximos 12 meses, entendiendo que Daabon es un actor que ya estaba aquí.

¿Qué tipo de pacientes tratan en Canadá y cuáles tratarían en Colombia?
Nosotros lo dividimos en cuatro grandes capítulos. El primero, está relacionado con el dolor y a su vez tiene tres subcategorías: localizado, neuropático y crónico. Después, tenemos pacientes con epilepsia, con un fuerte enfoque en niños. El tercer grupo son pacientes relacionados con asuntos dermatológicos como acné, psoriasis, dermatitis atópica, eczema y piel de mariposa. Y, por último, están los productos para oncología que funcionan en dos vías, una: para controlar el dolor y para el cuidado paliativo, y con el otro, tratamos la reducción de tumores.

¿Qué opinión le deja el marco regulatorio colombiano?
El cambio legislativo ha representado un gran esfuerzo y la regulación está avanzando. En Avicanna estamos entusiasmados por hacer parte de este momento histórico y sabemos que nuestro conocimiento será un aporte importante para el país.

Click Here

Cannabis, cara y sello

Cannabis, cara y sello

Hay una sola definición de la palabra marihuana, pero parece que cada quien le da un significado diferente.

El cannabis o la marihuana es, en esencia, una planta que generalmente se fuma como cigarrillo y produce sensaciones euforizantes pero… Conocí a una señora con un cáncer cerebral que solo tomándose las gotas de un aceite de marihuana podía espantar el terrible dolor de cabeza y descansar; para ella significaba paz. También a un doctor que trataba a drogadictos, muchos de los cuales comenzaron su camino hacia la adicción con un porro de marihuana; para él significa más bien peligro. Para los cientos de empresarios que asistieron a Expocannabiz 2019, que se realizó entre el 9 y el 11 de mayo en Cartagena, significa la oportunidad de entrar y permanecer en un negocio que podría alcanzar un mercado global de 146.000 millones de dólares en 2025, según un informe de Grand View Research.

Y conocí a Jim Belushi, un actor que se fumó su primer ‘porro’ cuando era apenas un adolescente y que hace tres años se dedica a cultivar marihuana en su finca de Oregón, EE.UU. Para él significa medicina, y no solo física, sino espiritual.

I. Jim Belushi.
II. Otras opiniones.

¿Pero quién convence de las bondades de la marihuana a las personas que protestaron ayer afuera del Centro de Convenciones -donde se realizó Exponcannabiz 2019- en contra, incluso, de legalizar la marihuana con fines medicinales? Quién, si ellos consideran que es la responsable, precisamente, de que sus familias colapsaran: son parientes de adictos que comenzaron fumándose un ‘porro’ y terminaron recluidos en clínicas de salud mental, sintiendo que no podían vivir sin drogas.

Para ellos y para el psiquiatra Christian Ayola, que ha tratado a muchos adictos, “la ‘marihuana medicinal’ no es otra cosa que un gran negocio promovido por el capitalismo internacional a través de las multinacionales farmacéuticas con el fin de posicionar a la marihuana como producto de consumo masivo, igual que el tabaco, el alcohol o las bebidas gaseosas, sin tener en cuenta el grave perjuicio para la salud mental y el riesgo psicosocial consecuente que comporta para jóvenes y adolescentes, quienes ven justificado el consumo de esta sustancia psicotrópica.

“El uso del cannabis medicinal, cuyos beneficios no están asegurados por el nivel de evidencia en las publicaciones, no pasa del posible o probable efecto terapéutico. Faltan estudios concluyentes, así como análisis que permitan verificar que los presuntos beneficios sobrepasan ampliamente la media de los placebos, y que superan a otros productos farmacéuticos mejor estudiados para los mismos trastornos, en los que se supone que tendría algún efecto positivo como: la náusea o la anorexia del paciente en quimioterapia, o el alivio del dolor para quien padece un síndrome doloroso crónico.

“A mi juicio, para los jóvenes de Colombia, que viven una situación social crítica, algunos en condición de vulnerabilidad, la legalización de la ‘marihuana medicinal’ constituye un factor de riesgo, debido a que es un mensaje equivocado que les ayuda a construir argumentos que justifican el consumo. Y es la puerta de entrada al uso de otras drogas, al tráfico, y a otras formas del delito”, concluye el psiquiatra.

III. Protesta y respuesta.

Al finalizar su conferencia, Jim supo sobre un grupo de personas que protestarían en las afueras del Centro de Convenciones contra Expocannabiz y esto es lo que le dijo al respecto:

“Pienso que necesitan alguna educación sobre marihuana, pienso que estas personas y las personas que ellos dicen (los adictos) están probablemente usando otras drogas como cocaína. No recomiendo mezclar marihuana con nada más, incluyendo alcohol, me siento mal porque ellos se sienten enojados, me siento mal porque probablemente sus familiares están sufriendo de adicciones y lo entiendo, porque mi hermano murió por la adicción y yo no estaría aquí ahora si pensara que la marihuana fue la causa de la muerte de mi hermano John, fue la cocaína”.

Habla un empresario

La opinión de Carlos Maldonado, director Médico de la biofarmacéutica Avicanna y participante de Expocannabiz, se contrapone a la del doctor Christian Ayola.

Hay quienes aseguran que la marihuana es la puerta para adicciones y excesos, y que eventos como Expocannabiz envían un mensaje peligroso a los jóvenes: los invitan a consumir sin contarles de los riesgos. ¿Qué tiene usted para decir al respecto?

“Es un reto, hoy la actividad educativa, la participación de médicos, de centros de investigación están dando data clínica muy interesante y destaca la importancia que tienen los resultados en términos de eficacia de estas sustancias, que sin duda debe educar más a la gente e involucrar más médicos, a los pacientes y la comunidad en general para que comprendan la dimensión desde el punto de vista terapéutico de estos medicamentos basados en cannabis”.

Click Here